INCY vs REGN: How Incyte Corporation and Regeneron Pharmaceuticals Compare (2026)
Last updated July 2026
Short answer
REGN is the larger of the two ($65.50B market cap): the incumbent the market prices for continued execution (11.62x forward earnings, beta 0.24). INCY is the smaller challenger ($23.32B), actually pricier on forward earnings (13.83x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
INCY vs REGN: the tie-breaker metrics
Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | INCY | REGN | What it tells you |
|---|---|---|---|
| Market cap | $23.32B | $65.50B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 13.83 | 11.62 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 16.48 | 15.25 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.76 | 0.24 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 96% of range | 33% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 4.15 | 2.03 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: REGN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how INCY and REGN affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. INCY and REGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined INCY and REGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Incyte Corporation (INCY) do?
Incyte Corporation is a Wilmington, Delaware based biopharmaceutical company that discovers, develops, and commercializes drugs in oncology, hematology, and dermatology. Its flagship product is Jakafi (ruxolitinib), an oral JAK inhibitor approved for myelofibrosis, polycythemia vera, and graft-versus-host disease, which still generates the largest share of company revenue (roughly $758 million in Q1 2026, up about 7%). Beyond Jakafi, Incyte sells the topical cream Opzelura (ruxolitinib) for atopic dermatitis and vitiligo, plus a widening hematology and oncology lineup including Monjuvi/Minjuvi, Niktimvo, and Zynyz, and it funds a broad clinical pipeline of oncology and immunology candidates.
What does Regeneron Pharmaceuticals (REGN) do?
Regeneron makes money primarily through two large franchises. Dupixent, an anti-inflammatory antibody used for eczema, asthma, COPD, and other conditions, is developed and commercialized in collaboration with Sanofi, and Regeneron records its share through Sanofi collaboration revenue (about $1.6 billion in Q1 2026, up roughly 36%). Eylea and the higher-dose Eylea HD treat retinal diseases such as wet age-related macular degeneration and diabetic eye disease, generating combined U.S. net product sales of about $941 million in Q1 2026, with Eylea HD now roughly half of that mix. Libtayo in oncology and a pipeline of nearly 50 clinical candidates round out the revenue base.
INCY vs REGN: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- INCY drivers: Jakafi franchise still growing near-term; Non-Jakafi revenue diversification.
- REGN drivers: Dupixent keeps compounding; A deep, diversified pipeline.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is revenue concentration: Jakafi still drives the majority of sales and faces US loss of exclusivity in December 2028, after which generic ruxolitinib is expected to erode the franchise. For REGN, the clearest risk is Eylea biosimilar erosion.
INCY or REGN: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick INCY if you believe its drivers more; REGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the INCY and REGN guides.
INCY vs REGN: the full fundamentals
INCY. Incyte trades at a modest multiple for a profitable biopharma, with a forward P/E around 12x reflecting strong recent earnings growth but investor caution about the 2028 Jakafi cliff. The trailing P/E collapsed from triple digits in early 2025 to the mid-teens through 2026 as earnings normalized. Figures are approximate as of mid-2026 and move with reported results and the share price.
REGN. Figures are approximate and tied to the asOf date; verify current numbers with a live quote before acting. Regeneron reported about 19% revenue growth and adjusted EPS of roughly $9.47 in Q1 2026, beating estimates, and authorized an additional $3 billion buyback. The mid-teens P/E reflects the market weighing strong Dupixent growth against expected Eylea biosimilar erosion.
Headline figures (approximate, JULY 2026): INCY shows revenue (ttm) ~$4.8B, q1 2026 revenue ~$1.27B (up ~21% YoY), jakafi q1 2026 net sales ~$758M, cash & marketable securities ~$4.0B; REGN shows total revenue (ttm, approx) ~$14 billion, q1 2026 total revenue ~$3.6 billion (up ~19% YoY), dupixent global net sales (q1 2026) ~$4.9 billion (up ~31%), eylea + eylea hd u.s. net sales (q1 2026) ~$941 million combined.
The bottom line: INCY vs REGN
INCY and REGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined INCY and REGN exposure against your real portfolio. It is not an investment adviser.
Build a basket around INCY with Walnut
Use Incyte Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the difference between INCY and REGN?
+
Incyte Corporation is a Wilmington, Delaware based biopharmaceutical company that discovers, develops, and commercializes drugs in oncology, hematology, and dermatology. Regeneron makes money primarily through two large franchises. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is INCY or REGN the better stock?
+
Neither is universally better. REGN is the larger incumbent; INCY is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, INCY or REGN?
+
On forward P/E (as of July 2026), INCY trades at 13.83x and REGN at 11.62x, so REGN is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both INCY and REGN?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of INCY vs REGN?
+
INCY: The dominant risk is revenue concentration: Jakafi still drives the majority of sales and faces US loss of exclusivity in December 2028, after which generic ruxolitinib is expected to erode the franchise. Pipeline and launch execution carry real uncertainty, as shown by the FDA's rejection of the once-daily extended-release Jakafi formulation, and clinical trials can fail at any stage. Competition is intensifying from larger peers with deeper resources in both oncology (Bristol Myers Squibb, Novartis, AbbVie) and inflammation/dermatology (AbbVie's Rinvoq, Eli Lilly's Olumiant, Pfizer, Regeneron). Morningstar has downgraded Incyte's economic moat toward none, citing the looming patent loss. If non-Jakafi revenue does not scale to the $3 billion to $4 billion goal in time, the company could face a revenue gap late this decade. REGN: The clearest risk is Eylea biosimilar erosion. Amgen's Pavblu launched in late 2024 and pressured sales, and settlements clear paths for Sandoz, and Alvotech and Teva, to launch competing copies in the U.S. around the fourth quarter of 2026, with erosion expected to accelerate. Eylea HD and Dupixent growth are the offsets, but the timing gap matters. The business is also concentrated in a few franchises, so a single setback in Dupixent or a major pipeline failure would weigh heavily, and the collaboration structure with Sanofi means Regeneron does not control all of its largest product's economics.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell INCY or REGN; figures are approximate and dated (as of July 2026). Verify current data before investing.